November 21, 2024
Suitable preclinical models are needed to evaluate therapies targeting specific pathways which affect brain cancer. Patient-derived xenograft (PDX) models are known to closely reflect human heterogeneity and provide the most accurate approach to predicting an agent’s efficacy prior to entering the clinic. The Crown Bioscience brain cancer PDX collection consists of a wide range of models, including several orthotopic models to more closely recapitulate the tumor microenvironment. More
PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience's HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBER | CANCER TYPE | CANCER SUBTYPE | DESCRIPTION | # per page |
---|---|---|---|---|
BN0769 | Brain Cancer | Meningeoma | Meningeoma | CLICK TO VIEW |
BN10438 | Brain Cancer | GBM | NA | CLICK TO VIEW |
BN13331 | Brain Cancer | Meningeoma | Meningioma. Pathol comment: C/W REFERRING DIAGNOSIS. ENTIRE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
BN15385 | Brain Cancer | GBM | N/A | CLICK TO VIEW |
BN2276 | Brain Cancer | GBM | Pleomorphic glioblastoma of right frontal lobe (WHO grade IV), highly pleomorphic nuclear with irregular form and a few mitoses, microvascular proliferation, haemorrhage, palisading necrosis. | CLICK TO VIEW |
BN2287 | Brain Cancer | Glioma | Anaplastic oligodendrogliomas (WHO grade III). IHC results: GFAP(+), Ki-67(+ <15%), S-100(-), Syn(-). | CLICK TO VIEW |
BN2289 | Brain Cancer | Glioma | Anaplastic oligodendrogliomas (WHO grade III). IHC results: GFAP(+), S-100(+), Syn(-), Ki-67(10% +), MMP-9(-), MGMT(-), P53(-), PCNA(+), P170(+). | CLICK TO VIEW |
BN2331 | Brain Cancer | Glioma | Anaplastic (malignant) meningeoma (WHO grade III). The tumor come from meninx or anfractuosity and infiltrate to brain parenchyma. The tumor show epithelial and fibrous feature. IHC results: GFAP(-), Vim(+++), EMA(+~++), Ki-67(>50%). | CLICK TO VIEW |
BN2338 | Brain Cancer | Glioma | Astrocytoma, grade II. | CLICK TO VIEW |
BN3733 | Brain Cancer | GBM | Right frontotemporal area: pleomorphic xanthoastrocytoma, WHO grade II | CLICK TO VIEW |
BN3801 | Brain Cancer | NA | NA | CLICK TO VIEW |
BN4027 | Brain Cancer | Glioma | N/A | CLICK TO VIEW |
BN4045 | Brain Cancer | GBM | NA | CLICK TO VIEW |
BN5457 | Brain Cancer | NA | Brain Tumor | CLICK TO VIEW |
BN5459 | Brain Cancer | NA | Meningioma. Atypical menigioma. | CLICK TO VIEW |
BN5463 | Brain Cancer | NA | Glioblastoma Multiforme | CLICK TO VIEW |
BN5474 | Brain Cancer | Glioblastoma | Glioblastoma | CLICK TO VIEW |
BN6299 | Brain Cancer | Glioma | Glioma | CLICK TO VIEW |
BN6300 | Brain Cancer | Astrocytoma | Glioma | CLICK TO VIEW |
BN6303 | Brain Cancer | Glioma | NA | CLICK TO VIEW |
BN6304 | Brain Cancer | Astrocytoma | Occipital lobe of brain: malignant tumor | CLICK TO VIEW |
BN9224 | Brain Cancer | GBM | NA | CLICK TO VIEW |
Already Registered? Login
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy